---
name: aria-estimation
description: >
  Regulatory project cost and timeline estimation framework with three-point estimates.
  Provides optimistic/expected/pessimistic cost ranges and milestone-based timeline breakdowns.
allowed-tools: Read Grep Glob
user-invocable: false
metadata:
  version: "1.0.0"
  category: "domain"
  status: "active"
  updated: "2026-02-11"
  modularized: "false"
  tags: "estimation, cost, timeline, budget, three-point, milestones"
  knowledge-base-date: "2026-01"

# MoAI Extension: Progressive Disclosure
progressive_disclosure:
  enabled: true
  level1_tokens: 100
  level2_tokens: 2200

# MoAI Extension: Triggers
triggers:
  keywords: ["estimate", "cost", "timeline", "budget", "schedule"]
  phases: ["run"]
---

# Regulatory Cost & Timeline Estimation Skill

## Quick Reference

**Purpose**: Provide three-point cost and timeline estimates for regulatory submissions based on pathway selections.

**Input**: Pathway selection results from `/aria:pathway`
**Output**: Cost breakdown (optimistic/expected/pessimistic), timeline with milestones, traffic light indicator
**Knowledge Base Date**: 2026-01

---

## Cost Estimation Framework

### Cost Categories

1. **Consulting Services (ì»¨ì„¤íŒ… ë¹„ìš©)**
   - Regulatory strategy consulting
   - Documentation review and guidance
   - Submission preparation support

2. **Testing & Validation (ì‹œí—˜ ë¹„ìš©)**
   - Biocompatibility testing
   - Electrical safety testing
   - Performance testing
   - Sterilization validation (if applicable)
   - Software validation (if applicable)

3. **Regulatory Fees (ê·œì œ ìˆ˜ìˆ˜ë£Œ)**
   - FDA user fees (510(k), PMA, De Novo)
   - MFDS application fees
   - Annual establishment fees

4. **Notified Body Fees (ì¸ì¦ ê¸°ê´€ ë¹„ìš©)** (EU only)
   - Initial assessment
   - QMS audit
   - Annual surveillance

5. **Clinical Study Costs (ì„ìƒì‹œí—˜ ë¹„ìš©)** (if applicable)
   - IRB fees
   - Patient recruitment
   - Data collection and analysis
   - Clinical study report

---

## Three-Point Cost Estimation

### Class I Devices

| Region | Pathway | Optimistic | Expected | Pessimistic | Categories |
|--------|---------|------------|----------|-------------|------------|
| FDA | 510(k) Exempt | â‚©5-10M | â‚©10-20M | â‚©20-30M | Consulting 40%, Testing 30%, Fees 30% |
| FDA | 510(k) Required | â‚©15-25M | â‚©25-40M | â‚©40-60M | Consulting 35%, Testing 35%, Fees 30% |
| EU MDR | Self-Declaration | â‚©8-15M | â‚©15-25M | â‚©25-40M | Consulting 45%, Testing 35%, Docs 20% |
| MFDS | Grade 1 ì‹ ê³  | â‚©5-12M | â‚©12-20M | â‚©20-35M | Consulting 40%, Testing 35%, Fees 25% |

### Class II / IIa Devices

| Region | Pathway | Optimistic | Expected | Pessimistic | Categories |
|--------|---------|------------|----------|-------------|------------|
| FDA | 510(k) | â‚©30-60M | â‚©60-100M | â‚©100-150M | Consulting 30%, Testing 40%, Fees 20%, Docs 10% |
| EU MDR | IIa NB | â‚©40-80M | â‚©80-130M | â‚©130-200M | Consulting 25%, Testing 35%, NB 25%, Docs 15% |
| MFDS | Grade 2 í—ˆê°€ | â‚©30-70M | â‚©70-120M | â‚©120-180M | Consulting 30%, Testing 45%, Fees 15%, Docs 10% |

### Class II / IIb Devices

| Region | Pathway | Optimistic | Expected | Pessimistic | Categories |
|--------|---------|------------|----------|-------------|------------|
| FDA | De Novo | â‚©80-120M | â‚©120-200M | â‚©200-300M | Consulting 30%, Testing 35%, Special Controls 20%, Fees 15% |
| EU MDR | IIb NB | â‚©70-120M | â‚©120-180M | â‚©180-280M | Consulting 25%, Testing 30%, NB 30%, PMCF 15% |

### Class III Devices

| Region | Pathway | Optimistic | Expected | Pessimistic | Categories |
|--------|---------|------------|----------|-------------|------------|
| FDA | PMA | â‚©200-400M | â‚©400-800M | â‚©800-1,500M | Consulting 20%, Testing 25%, Clinical 40%, Fees 10%, QMS 5% |
| EU MDR | Class III CI | â‚©180-350M | â‚©350-700M | â‚©700-1,200M | Consulting 20%, Testing 20%, Clinical 35%, NB 20%, QMS 5% |
| MFDS | Grade 4 CT | â‚©150-300M | â‚©300-600M | â‚©600-1,000M | Consulting 20%, Testing 25%, Clinical 40%, Fees 10%, QMS 5% |

---

## Timeline Estimation Framework

### Milestone-Based Timeline

#### 510(k) Pathway (FDA Class II)

**Phase 1: Preparation (ì¤€ë¹„)**
- Duration: 1-2ê°œì›”
- Deliverables: Predicate device identification, Gap analysis, Test protocol development

**Phase 2: Testing (ì‹œí—˜)**
- Duration: 2-4ê°œì›”
- Deliverables: Biocompatibility, Electrical safety, Performance testing

**Phase 3: Documentation (ë¬¸ì„œí™”)**
- Duration: 1-2ê°œì›”
- Deliverables: 510(k) submission package, Substantial equivalence report

**Phase 4: Submission & Review (ì œì¶œ ë° ì‹¬ì‚¬)**
- Duration: 3-6ê°œì›” (standard) or 1-3ê°œì›” (expedited)
- Deliverables: FDA submission, Deficiency response (if any)

**Total Timeline**:
- Optimistic: 3-6ê°œì›”
- Expected: 6-9ê°œì›”
- Pessimistic: 9-12ê°œì›”

#### PMA Pathway (FDA Class III)

**Phase 1: IDE Preparation**
- Duration: 2-4ê°œì›”
- Deliverables: IDE application, IRB approval

**Phase 2: Clinical Study**
- Duration: 12-24ê°œì›”
- Deliverables: Patient enrollment, Data collection, Clinical study report

**Phase 3: PMA Documentation**
- Duration: 3-6ê°œì›”
- Deliverables: PMA submission package, Manufacturing QMS documentation

**Phase 4: FDA Review**
- Duration: 6-12ê°œì›”
- Deliverables: FDA panel meeting, Deficiency responses, Approval

**Total Timeline**:
- Optimistic: 12-18ê°œì›”
- Expected: 18-30ê°œì›”
- Pessimistic: 30-48ê°œì›”

#### EU MDR Class IIa (Notified Body)

**Phase 1: Preparation**
- Duration: 1-3ê°œì›”
- Deliverables: Notified Body selection, Technical file structure

**Phase 2: Testing & CER**
- Duration: 3-6ê°œì›”
- Deliverables: Testing, Clinical Evaluation Report, PMSP

**Phase 3: Notified Body Assessment**
- Duration: 2-4ê°œì›”
- Deliverables: Technical file submission, QMS audit, Certificate

**Total Timeline**:
- Optimistic: 6-9ê°œì›”
- Expected: 9-13ê°œì›”
- Pessimistic: 13-18ê°œì›”

#### MFDS Grade 2 (í—ˆê°€)

**Phase 1: Preparation**
- Duration: 1-2ê°œì›”
- Deliverables: Test protocol, Documentation plan

**Phase 2: Testing**
- Duration: 2-4ê°œì›”
- Deliverables: Non-clinical testing, Performance validation

**Phase 3: Documentation**
- Duration: 1-2ê°œì›”
- Deliverables: Approval application package

**Phase 4: MFDS Review**
- Duration: 2-4ê°œì›”
- Deliverables: Application submission, Deficiency response

**Total Timeline**:
- Optimistic: 3-6ê°œì›”
- Expected: 6-10ê°œì›”
- Pessimistic: 10-14ê°œì›”

---

## Workflow

### Step 1: Load Pathway Data

Use pathway results from prior `/aria:pathway` execution:
- Check for `.aria/products/<product-name>/<date>/pathway.summary.md`
- Extract selected pathways for each target region
- If pathway data NOT available:
  - Display warning: **"âš ï¸ ê²½ë¡œ ì„ íƒ ë°ì´í„°ê°€ í•„ìš”í•©ë‹ˆë‹¤. ë¨¼ì € `/aria:pathway` ëª…ë ¹ì„ ì‹¤í–‰í•˜ì„¸ìš”."**
  - Traffic Light: ğŸŸ¡ YELLOW
  - STOP workflow

### Step 2: Apply Cost Estimation Logic

Based on loaded pathway data:

**For each region**:
1. Identify pathway type (510(k), PMA, De Novo, CE Mark, ì‹ ê³ , í—ˆê°€, etc.)
2. Determine device class/grade
3. Lookup cost ranges from framework above
4. Apply three-point estimate (optimistic, expected, pessimistic)
5. Break down by cost categories

**Multi-region scenarios**:
- Identify shared costs (common testing, consulting overlap)
- Calculate total cost range accounting for shared activities
- Highlight cost-saving opportunities from parallel submissions

### Step 3: Apply Timeline Estimation Logic

Based on loaded pathway data:

**For each region**:
1. Identify pathway milestones
2. Assign duration ranges to each phase
3. Calculate total timeline (optimistic/expected/pessimistic)

**Multi-region scenarios**:
- Identify critical path (longest timeline)
- Show parallel vs. sequential track options
- Highlight timeline dependencies

### Step 4: Assign Traffic Light

- **ğŸŸ¢ GREEN**: Total cost < â‚©150M, timeline < 12 months
- **ğŸŸ¡ YELLOW**: Total cost â‚©150-500M or timeline 12-24 months or clinical study required
- **ğŸ”´ RED**: Not used (all pathways have estimates)

### Step 5: Generate Output

Output structure (Korean language):

```markdown
# ë¹„ìš© ë° ì¼ì • ì¶”ì • ê²°ê³¼

## ì œí’ˆ ì •ë³´
- ì œí’ˆëª…: [Product Name]
- ë¶„ì„ ì¼ì: [YYYY-MM-DD]
- ëŒ€ìƒ ì‹œì¥: [Target Markets]

## ë¹„ìš© ì¶”ì •

### ì´ ë¹„ìš© ë²”ìœ„

| ì‹œë‚˜ë¦¬ì˜¤ | ë¹„ìš© ë²”ìœ„ (â‚©) |
|---------|--------------|
| ë‚™ê´€ì  (Optimistic) | [X]-[Y]M |
| ì˜ˆìƒ (Expected) | [Y]-[Z]M |
| ë¹„ê´€ì  (Pessimistic) | [Z]-[W]M |

### ë¹„ìš© ì¹´í…Œê³ ë¦¬ ë¶„ì„

#### FDA (ë¯¸êµ­)
- **ì»¨ì„¤íŒ…**: [X]%
- **ì‹œí—˜**: [Y]%
- **ê·œì œ ìˆ˜ìˆ˜ë£Œ**: [Z]%
- **ì„ìƒì‹œí—˜** (í•´ë‹¹ì‹œ): [W]%

**ë¹„ìš© ë²”ìœ„**:
- ë‚™ê´€ì : â‚©[X]M
- ì˜ˆìƒ: â‚©[Y]M
- ë¹„ê´€ì : â‚©[Z]M

#### EU MDR (ìœ ëŸ½)
- **ì»¨ì„¤íŒ…**: [X]%
- **ì‹œí—˜**: [Y]%
- **ì¸ì¦ ê¸°ê´€**: [Z]%
- **ë¬¸ì„œí™”**: [W]%

**ë¹„ìš© ë²”ìœ„**:
- ë‚™ê´€ì : â‚©[X]M
- ì˜ˆìƒ: â‚©[Y]M
- ë¹„ê´€ì : â‚©[Z]M

#### MFDS (í•œêµ­)
- **ì»¨ì„¤íŒ…**: [X]%
- **ì‹œí—˜**: [Y]%
- **ê·œì œ ìˆ˜ìˆ˜ë£Œ**: [Z]%
- **ë¬¸ì„œí™”**: [W]%

**ë¹„ìš© ë²”ìœ„**:
- ë‚™ê´€ì : â‚©[X]M
- ì˜ˆìƒ: â‚©[Y]M
- ë¹„ê´€ì : â‚©[Z]M

### ë‹¤ì¤‘ ì‹œì¥ ë¹„ìš© ì ˆê° ê¸°íšŒ
- **ê³µí†µ ì‹œí—˜ í™œìš©**: [Shared testing activities]
- **ì»¨ì„¤íŒ… í†µí•©**: [Consulting overlap]
- **ë³‘ë ¬ ì œì¶œ ì´ì **: [Parallel submission benefits]

## ì¼ì • ì¶”ì •

### ì´ ì†Œìš” ê¸°ê°„

| ì‹œë‚˜ë¦¬ì˜¤ | ê¸°ê°„ |
|---------|------|
| ë‚™ê´€ì  | [X]-[Y]ê°œì›” |
| ì˜ˆìƒ | [Y]-[Z]ê°œì›” |
| ë¹„ê´€ì  | [Z]-[W]ê°œì›” |

### ì£¼ìš” ë§ˆì¼ìŠ¤í†¤

#### FDA (ë¯¸êµ­) - [Pathway Name]
1. **ì¤€ë¹„ ë‹¨ê³„**: [X-Y]ê°œì›”
   - Deliverables: [...]
2. **ì‹œí—˜ ë‹¨ê³„**: [Y-Z]ê°œì›”
   - Deliverables: [...]
3. **ë¬¸ì„œí™”**: [Z-W]ê°œì›”
   - Deliverables: [...]
4. **ì‹¬ì‚¬**: [W-V]ê°œì›”
   - Deliverables: [...]

**ì´ ì†Œìš” ê¸°ê°„**: [X-Y]ê°œì›” (ë‚™ê´€), [Y-Z]ê°œì›” (ì˜ˆìƒ), [Z-W]ê°œì›” (ë¹„ê´€)

#### EU MDR (ìœ ëŸ½) - [Pathway Name]
[Similar milestone breakdown]

#### MFDS (í•œêµ­) - [Pathway Name]
[Similar milestone breakdown]

### ìµœì¥ ê²½ë¡œ (Critical Path)
- **ì§€ì—­**: [Region]
- **ì˜ˆìƒ ì†Œìš” ê¸°ê°„**: [Duration]
- **ì£¼ìš” ë³‘ëª© êµ¬ê°„**: [Bottleneck phase]

## ìœ„í—˜ë„ í‰ê°€
- **Traffic Light**: [ğŸŸ¢ GREEN / ğŸŸ¡ YELLOW]
- **í‰ê°€**: [Risk assessment]

[If YELLOW]: **âš ï¸ ì£¼ì˜**: ì´ ì¶”ì •ì¹˜ëŠ” ë¶ˆí™•ì‹¤ì„±ì´ ë†’ìŠµë‹ˆë‹¤. ì„ìƒì‹œí—˜ ì†Œìš” ê¸°ê°„, ì‹¬ì‚¬ ê¸°ê°„, ì¸ì¦ ê¸°ê´€ ëŒ€ê¸° ì‹œê°„ ë“±ì€ ë³€ë™ ê°€ëŠ¥ì„±ì´ í½ë‹ˆë‹¤.

## ë¹„ìš© ì ˆê° ì „ëµ
1. [Cost-saving strategy 1]
2. [Cost-saving strategy 2]
3. [Cost-saving strategy 3]

## ë‹¤ìŒ ë‹¨ê³„ ì œì•ˆ
1. `/aria:plan` ëª…ë ¹ìœ¼ë¡œ ì„¸ë¶€ ì‹¤í–‰ ê³„íš ìˆ˜ë¦½
2. ì˜ˆì‚° í™•ë³´ ë° ë‚´ë¶€ ìŠ¹ì¸ ì ˆì°¨ ì§„í–‰
3. ì»¨ì„¤íŒ… ì—…ì²´ ë° ì‹œí—˜ ê¸°ê´€ ê²¬ì  ìš”ì²­

## ë©´ì±… ì¡°í•­
âš ï¸ **ë³¸ ìë£ŒëŠ” ì°¸ê³  ì •ë³´ì´ë©°, í™•ì • ê²¬ì ì´ ì•„ë‹™ë‹ˆë‹¤.** ì‹¤ì œ ë¹„ìš©ê³¼ ì¼ì •ì€ ì œí’ˆ ë³µì¡ë„, ì‹œí—˜ ê²°ê³¼, ê·œì œ ê¸°ê´€ ìš”êµ¬ì‚¬í•­, ì‹œì¥ ìƒí™© ë“±ì— ë”°ë¼ í¬ê²Œ ë‹¬ë¼ì§ˆ ìˆ˜ ìˆìŠµë‹ˆë‹¤. íŠ¹íˆ Class III ì˜ë£Œê¸°ê¸°ì˜ ê²½ìš° ì„ìƒì‹œí—˜ ë¹„ìš©ê³¼ ê¸°ê°„ì˜ ë¶ˆí™•ì‹¤ì„±ì´ ë§¤ìš° ë†’ìŠµë‹ˆë‹¤. ì‹¤ì œ í”„ë¡œì íŠ¸ ì§„í–‰ ì „ ì „ë¬¸ ì»¨ì„¤íŒ… ì—…ì²´ì™€ ìƒì„¸ ê²¬ì ì„ ë°›ìœ¼ì‹œê¸° ë°”ëë‹ˆë‹¤.

---
**ìƒì„± ì¼ì‹œ**: [Timestamp]
**ARIA Plugin Version**: 2.0.0
**ë°ì´í„° ì¶œì²˜**: ê·œì œ ì»¨ì„¤íŒ… ì—…ê³„ í‰ê·  ë¹„ìš© (2026-01 ê¸°ì¤€)
```

### Step 6: Generate Context Simplifier Summary

Create `.summary.md` file for downstream pipeline:

```markdown
# Estimation Summary

**Product**: [Product Name]
**Date**: [YYYY-MM-DD]

## Cost Ranges
- **Optimistic**: â‚©[X]M
- **Expected**: â‚©[Y]M
- **Pessimistic**: â‚©[Z]M

## Timeline Ranges
- **Optimistic**: [X]ê°œì›”
- **Expected**: [Y]ê°œì›”
- **Pessimistic**: [Z]ê°œì›”

## Critical Path
- **Region**: [Region]
- **Duration**: [Duration]

## Traffic Light
- **Overall Risk**: [GREEN/YELLOW]

---
This summary is consumed by `/aria:plan` command.
```

---

## Data Source Strategy

1. **Built-in Knowledge** (Primary): Industry average costs and timelines (2026-01)
2. **Loaded Pathway Data** (Input): `.summary.md` from `/aria:pathway`
3. **External Tools** (Supplementary): Only when explicitly configured

**Note**: Cost ranges are based on Korean regulatory consulting industry averages as of 2026-01. Actual costs vary by project complexity, testing requirements, and market conditions.

---

## Output Template (Korean)

See Step 5 for complete output structure. All user-facing text MUST be in Korean except:
- Currency symbols (â‚©)
- Technical abbreviations (FDA, PMA, QMS, etc.)

---

## Traffic Light Definitions

- **ğŸŸ¢ GREEN**: Low cost/short timeline (< â‚©150M, < 12 months)
- **ğŸŸ¡ YELLOW**: Moderate-high cost/long timeline (â‚©150-500M, 12-24 months, clinical study)
- **ğŸ”´ RED**: Not used (all pathways have estimates)

---

## Escalation Scenarios

Highlight high uncertainty when:
- Clinical trials required (cost Â±50%, timeline Â±100%)
- Class III devices (PMA, EU MDR Class III, MFDS Grade 4)
- Novel device categories (De Novo pathway)
- Multi-region submissions with regulatory conflicts

---

## VALID Framework Compliance

- **Verified**: Cost ranges cite industry average data sources (2026-01)
- **Accurate**: Estimates reflect current regulatory timelines and consulting rates
- **Linked**: References to pathway types from `/aria:pathway`
- **Inspectable**: Breakdown by cost categories and timeline phases transparent
- **Deliverable**: Output stored in `.aria/products/<product-name>/<date>/estimate.md`

---

## Version History

**v1.0.0** (2026-02-11):
- Initial implementation for Phase 3
- Three-point cost estimation (optimistic/expected/pessimistic)
- Milestone-based timeline framework
- Multi-region cost breakdown
- Context Simplifier integration
- Korean language output
- Traffic light system
- VALID framework compliance

---

**Knowledge Base Cutoff**: 2026-01
**Next Update**: Quarterly cost/timeline updates based on industry trends
